anti-MHC-I α3 domain monoclonal antibody

Anti-MHC-I α3 domain monoclonal antibodies are experimental immunotherapeutic agents designed to selectively disrupt the interaction between the α3 domain of major histocompatibility complex class I (MHC-I) molecules and the CD8α co-receptor on CD8+ T cells. Historically, the MHC-I α3 domain/CD8α interaction was viewed as a positive co-receptor interaction that stabilizes the T-cell receptor (TCR) complex during antigen recognition. However, recent preclinical research from Ohio State University has demonstrated that this axis also functions as a tonic inhibitory pathway that restrains peripheral CD8+ T-cell activation and maintains T-cell tolerance in vivo. By blocking this interaction, these monoclonal antibodies can activate CD8+ T cells in the absence of antigen, enhance antigen-specific T-cell responses, and prevent or reverse T-cell tolerance, representing a novel strategy for enhancing antitumor or antiviral immunity.

Other names

anti-MHC class I alpha3 domain monoclonal antibodyanti-MHC-I a3 domain monoclonal antibodyanti-MHC-I alpha3 domain monoclonal antibody